Print

AMS Guide to Equivalent HRT/MHT Doses

This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different HRT/MHT products available Sept 2016.  HRT is now referred to as Menopausal Hormone Therapy (MHT).  The intention is to help physicians change their patients to higher or lower approximate doses of HRT/MHT if needing to tailor therapy, or remain within the same approximate dose if needing to change brands of HRT/MHT.  Products marked (Aus) are Australia only and products marked (NZ) are NZ only.  Products with an * meaning Private/non PBS script.

pdfAMS Guide to Equivalent HRT-MHT114.84 KB

Oestrogen and progestogen combination MHT

Use cyclical oestrogen and progestogen combinations at peri-menopause or if less than 12 months amenorrhoea

Low Dose    
Product Presentation Composition
Femoston (Aus) tablet 1mg oestradiol/10mg dydrogesterone
Medium dose    
Trisequens* tablet 1 and 2mg oestradiol/1mg norethisterone
Femoston (Aus) tablet 2mg oestradiol/10mg dydrogesterone
Estalis sequi 50/140 (Aus) transdermal patch 50mcg 17 B oestradiol/140mcg norethisterone acetate (twice weekly application)
Estalis sequi 50/250 (Aus)
(same oestrogen, more progestogen than Estalis sequi 50/140)
transdermal patch 50mcg 17 B oestradiol/250mcg norethisterone acetate (twice weekly application)

Continuous oestrogen and progestogen combinations

Should be used if 12 months since LMP or after 12 months cyclical MHT

Low dose    
Product Presentation Composition
Angeliq1/2* (Aus) tablet 1mg oestradiol/2mg drospirenone
Femoston-conti (Aus) tablet 1mg oestradiol/5mg dydrogesterone
Kliovance* tablet 1mg oestradiol/0.5mg norethistrone
Livial*, Xyvion*
(generally suitable for older women or at least one year post-menopause)
tablet 2.5mg tibolone
Medium dose    
Kliogest* tablet 2mg oestradiol/1mg norethistrone
Premia 2.5 continous* tablet 0.625mg conjugated equine oestrogens/
2.5mg medroxyprogesterone acetate
Premia 5 continous* 
(same oestrogen, more progestogen than Premia 2.5 continuous)
tablet 0.625mg conjugated equine oestrogens/
5mg medroxyprogesterone acetate
Estalis continuous 50/140 (Aus) transdermal patch 50mcg 17 B oestradiol/140mcg norethisterone acetate (twice weekly application)
Estalis continuous 50/250 (Aus)
(same oestrogen, more progestogen than Estalis continuous 50/140)
transdermal patch 50mcg 17 B oestradiol/250mcg norethisterone acetate (twice weekly application)

Oestrogen only therapy

Only use these if patient has had a hysterectomy or in combination with a progestogen or Mirena if intact uterus

Low dose    
Product Presentation Composition
Estrofem* tablet 1mg 17 B oestradiol
Progynova tablet 1mg oestradiol valerate
Premarin* tablet 0.3mg conjugated equine oestrogen
Climara 25 transdermal patch 25mcg/24hrs 17 B oestradiol (weekly application)
Estradot 25 or 37.5 transdermal patch 25 or 37.5mcg/24hrs 17B oestradiol (twice weekly application)
Estraderm 25 MX (Aus) transdermal patch 25mcg/24hrs 17B oestradiol (twice weekly application)
Medium dose    
Estrofem*, Zumenon (Aus) tablet 2mg 17B oestradiol
Progynova tablet 2mg oestradiol valerate
Premarin* tablet 0.625mg conjugated equine oestrogens
Climara 50 transdermal patch 50mcg/24hours 17B oestradiol (weekly application)
Estradot 50,  Estraderm 50 MX (Aus) transdermal patch 50mcg/24 hours 17B oestradiol (twice weekly application)
Sandrena gel 1mg oestradiol (daily application)
High dose    
Climara 75 transdermal patch 75mcg/24hours oestradiol (weekly application)
Estradot 75, Estradot 100 transdermal patch 75 or 100mcg/24 hours (twice weekly application)
Climara 100 transdermal patch 100mcg/24hours oestradiol (weekly application)
Estraderm 100 MX (Aus) transdermal patch 100mcg/24hours 17B oestradiol (twice weekly application)
Oestradiol implants - No longer available
Oestrogen only vaginal therapy  
Product Presentation Composition
Ovestin cream 1mg/g oestriol
Vagifem Low pessary 10mcg oestradiol

Progestogen

Suggested alternative doses for use with the oestrogen preparations above where fixed dose therapy is not suitable

Low dose for use with low dose oestrogen
Product  Presentation  Composition
Provera (1/2 of 5mg tablet) tablet 2.5mg medroxyprogesterone acetate
Provera 2.5mg tablet* tablet 2.5mg medroxyprogesterone acetate
Primolut N (1/4 of 5mg tablet) tablet 1.25 mg norethisterone
Mirena* device (5 years) 20mcg/24hrs levonorgestrel
(PBS indication for contraception/menorrhagia)

Low dose progestogen-only contraceptive pills (Microlut (30mcg levonorgestrel), and Noriday (both 350mcg norethisterone) are used by some clinicians in various doses but there is limited data for dosages of these pills required for endometrial protection. 1 mg norethisterone was considered the minimum dose (cyclical or continuous) for adequate endometrial protection in the Cochrane Review (Cochrane Database Syst Rev. 2009 Apr 15;(2):CS000402).

Medium dose for use with medium dose estrogen
Product Presentation  Dose 
Primolut N (1/4 of 5mg tablet) tablet 1.25 mg norethisterone
Provera, Ralovera (Aus) tablet 5mg medroxyprogesterone acetate
Utrogestan (NZ), Prometrium* (Aus) capsule 100 mg micronised progesterone
Mirena* device (5 years) 20mcg/24hrs levonorgestrel
(PBS indication for contraception/menorrhagia)
Higher dose (for use in cyclical therapy or continuous therapy with high dose oestrogen)
Primolut N (1/2 5mg tablet) tablet 2.5mg norethisterone
Provera, Ralovera (Aus) tablet 10mg medroxyprogesterone acetate
Utrogestan (NZ)
Prometrium* (Aus)
capsule
capsule
200 mg micronised progesterone
2x100 mg micronised progesterone

AMS New directions in women's health

Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider.

This Information Sheet may contain copyright or otherwise protected material. Reproduction of this Information Sheet by Australasian Menopause Society Members and other health professionals for clinical practice is permissible. Any other use of this information (hardcopy and electronic versions) must be agreed to and approved by the Australasian Menopause Society.

Content Updated October 2016

cialis